Xili Technology
A research and development company whose mission is to harness advanced technologies, machine learning/AI, and the inherent biology embedded within RNA to develop novel medicines to treat human disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $30.0m | Series A | |
| Total Funding | 000k | ||
Related Content
ReviR Therapeutics, also known as Xili Technology, is a drug discovery company that leverages ribonucleic acid (RNA) and artificial intelligence (AI) to create new medicines. The company has developed the VoyageR AI platform, which is a machine learning system used for identifying and validating RNA drug targets. This platform is also capable of designing drugs and predicting their effectiveness.
ReviR's primary focus is on developing treatments for genetic diseases that currently have few or no therapeutic options. The company utilizes its SpliceR modulation technologies to target specific RNAs associated with these diseases. In addition to its work on genetic disorders, ReviR is also exploring applications in oncology, as evidenced by its research collaboration with Asieris Pharmaceuticals.
The company's business model appears to be centered on both internal drug development and strategic partnerships with other pharmaceutical companies. By combining computational biology with high-throughput drug discovery techniques, ReviR aims to accelerate the development of next-generation therapies for patients.
Keywords: drug discovery, RNA, artificial intelligence, machine learning, genetic diseases, oncology, therapeutics, computational biology, drug development, splice modulation